Reduced serum levels of pro-inflammatory chemokines in fragile X syndrome

BMC Neurology

Table 1 Characteristics of FXS patients and healthy controls

ID	Sex	Age ^#	BMI (kg/m²)	Time of sampling
Controls
C1	Male		17.4	15:10
C2	Female		16.9	13:40
C3	Male		16.9	13:44
C4	Male		17.9	16:57
C5	Male		14.4	11:10
C6	Male		20.1	07:40
C7	Male		19.4	10:28
C8	Female		18.9	14:05
C9	Female		19.9	13:55
C10	Male		18.0	10:40
C11	Male		21.4	16:20
C12	Male		23.5	14:45
C13	Male	Age range	22.1	13:40
C14	Female	of control	15.4	08:00
C15	Male	group:	21.4	07:15
C16	Male	5.7–19.3 yrs	25.2	07:15
C17	Male		22.4	07:40
C18	Male		14.6	17:00
C19	Male		16.4	17:38
C20	Male		20.2	17:20
C21	Male		22.2	17:26
C22	Male		15.4	16:45
C23	Male		16.4	17:05
C24	Male		14.8	16:00
C25	Male		13.9	16:10
C26	Female		18.9	15:40
C27	Male		13.8	12:53
C28	Male		17.1	06:45
C29	Male		19.6	07:45
FXS Patients
X1	Male		16.3	15:45
X2	Male		18.1	12:10
X3	Male		16.3	16:20
X4	Male		23.7	11:00
X5	Male		16.9	15:20
X6	Male		21.2	12:00
X7	Male		16.4	09:00
X8	Male		16.7	14:00
X9	Male		15.9	11:45
X10	Male		13.0	19:30
X11	Male	Age range	14.1	11:30
X12*	Male	of FXS	15.0	11:50
X13	Female	group:	18.4	10:45
X14	Male	6.3–17.9 yrs	16.9	10:55
X15	Male		18.3	10:15
X16	Female		19.5	10:20
X17	Female		34.5	07:40
X18	Male		15.9	13:25
X19	Male		15.8	10:45
X20	Male		38.8	19:30
X21	Male		19.0	09:20
X22	Male		20.1	13:50
X23	Female		24.8	09:15
X24	Male		18.9	09:10
X25*	Female		20.3	10:30
Control	82.7%	12.0	18.0	13:55
FXS	80.0%	12.5	18.1	11:30
p-value	1	0.3769	0.8803	0.2527

For the sex variable, percentage of males in each group and p-value for Fisher’s exact test are indicated. For the other variables, range or medians of each group and p-values for Mann & Whitney tests are indicated. Patients under treatment are labelled with *. (#) To preserve anonymity, instead of individual ages, age ranges are specified for each group

ISSN: 1471-2377